Starmab Biology (Suzhou) Co., Ltd. is jointly invested by the innovation drug research fund of Fosun Group and Yaopharma. The scientists and leadership team have a proven track record of innovation and successful drug development of therapeutic candidates from early discovery to commercial implementation.

Starmab mainly focuses on infectious diseases which are high mortality, high healthcare costs and high unmet need,  and develops novel anti-infective antibody drugs against super drug-resistant bacteria, fungi and viruses seriously endangering public health. The Company’s mission is to introduce much needed innovations on antibody drugs to infectious disease treatment. 

The R&D team used hybridoma technology and phage display technology to screen antibody molecules with anti-infective activity from immunized mice, alpaca or patients. And further develops antibody drugs for pre-emptive and post-infection therapy of the most serious infectious diseases.

The antimicrobial product candidates are highly differentiated from conventional anti-infective drugs in mechanisms of action, and will be developed using clinical study designs that allow for clear demonstration of superiority over standard of care anti-infective drugs.